Home
/
Cyclerion Therapeutics, Inc.
/
Financials
/
Quarterly
Cyclerion Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Cyclerion Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$875.0K
Nov 12, 2025
Q2
2025
Jun 30, 2025
$93.0K
Aug 5, 2025
Q1
2025
Mar 31, 2025
$81.0K
May 6, 2025
Q3
2025
Sep 30, 2024
$194.0K
Nov 12, 2025
Q2
2025
Jun 30, 2024
$0
Aug 5, 2025
Q1
2025
Mar 31, 2024
$0
May 6, 2025
Q3
2024
Sep 30, 2023
$0
Nov 14, 2024
Q2
2023
Jun 30, 2023
$0
Jul 28, 2023
Q1
2023
Mar 31, 2023
$0
May 12, 2023
Q3
2023
Sep 30, 2022
$0
Nov 13, 2023
Q2
2023
Jun 30, 2022
$306.0K
Jul 28, 2023
Q1
2023
Mar 31, 2022
$711.0K
May 12, 2023
Q3
2022
Sep 30, 2021
$348.0K
Nov 3, 2022
Q2
2022
Jun 30, 2021
$3.00M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$62.0K
May 4, 2022
Q3
2021
Sep 30, 2020
$400.0K
Nov 9, 2021
Q2
2021
Jun 30, 2020
$749.0K
Jul 29, 2021
Q1
2021
Mar 31, 2020
$1.01M
Apr 30, 2021
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2020
Sep 30, 2020
$400.0K
Nov 5, 2020
Q2
2020
Jun 30, 2020
$749.0K
Aug 3, 2020
Q1
2020
Mar 31, 2020
$1.01M
May 4, 2020
Q3
2020
Sep 30, 2019
$1.40M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$1.63M
Aug 3, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($976.0K)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($324.0K)
Aug 5, 2025
Q3
2025
Jun 30, 2025
($324.0K)
Nov 12, 2025
Q1
2025
Mar 31, 2025
($1.43M)
May 6, 2025
Q2
2025
Mar 31, 2025
($1.43M)
Aug 5, 2025
Q3
2025
Mar 31, 2025
($1.43M)
Nov 12, 2025
Q3
2025
Sep 30, 2024
($723.0K)
Nov 12, 2025
Q3
2025
Jun 30, 2024
($1.32M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($1.32M)
Aug 5, 2025
Q3
2025
Mar 31, 2024
($1.54M)
Nov 12, 2025
Q1
2025
Mar 31, 2024
($1.54M)
May 6, 2025
Q2
2025
Mar 31, 2024
($1.54M)
Aug 5, 2025
Q3
2024
Sep 30, 2023
$7.57M
Nov 14, 2024
Q3
2024
Jun 30, 2023
($4.18M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($4.18M)
Aug 7, 2024
Q2
2024
Mar 31, 2023
($6.95M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($6.95M)
May 7, 2024
Q3
2024
Mar 31, 2023
($6.95M)
Nov 14, 2024
Q3
2023
Sep 30, 2022
($10.50M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($13.39M)
Jul 28, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.01M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($1.67M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($1.46M)
May 6, 2025
Q3
2025
Sep 30, 2024
($1.13M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($1.38M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($1.62M)
May 6, 2025
Q3
2024
Sep 30, 2023
($6.02M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($1.87M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($3.28M)
May 7, 2024
Q3
2023
Sep 30, 2022
($4.52M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($13.43M)
Jul 28, 2023
Q1
2023
Mar 31, 2022
($12.98M)
May 12, 2023
Q3
2022
Sep 30, 2021
($11.29M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($16.18M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($13.40M)
May 4, 2022
Q3
2021
Sep 30, 2020
($21.78M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($19.67M)
Jul 29, 2021
Q1
2021
Mar 31, 2020
($20.59M)
Apr 30, 2021
Q3
2020
Sep 30, 2019
($28.02M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($33.05M)
Aug 3, 2020